• LAST PRICE
    50.6400
  • TODAY'S CHANGE (%)
    Trending Down-0.8600 (-1.6699%)
  • Bid / Lots
    50.0000/ 4
  • Ask / Lots
    67.7600/ 1
  • Open / Previous Close
    51.7800 / 51.5000
  • Day Range
    Low 50.3000
    High 52.8450
  • 52 Week Range
    Low 14.1900
    High 72.2900
  • Volume
    289,137
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 51.5
TimeVolumeAPGE
09:32 ET202652
09:34 ET10451.98
09:39 ET44651.98
09:41 ET50051.695
09:45 ET30051.3
09:48 ET10051.22
09:50 ET20051.71
09:52 ET40051.58
09:54 ET10051.53
09:56 ET50051.54
09:57 ET10051.52
09:59 ET164651.75
10:01 ET10051.84
10:03 ET10051.74
10:06 ET30051.95
10:12 ET20052.17
10:14 ET10052.195
10:15 ET40052.27
10:17 ET50052.235
10:19 ET40052.13
10:21 ET50052.04
10:26 ET90052.02
10:28 ET100052.05
10:30 ET167051.67
10:32 ET44951.85
10:33 ET157852.35
10:35 ET20051.97
10:37 ET40051.885
10:39 ET40051.99
10:42 ET170951.935
10:46 ET20051.93
10:48 ET50051.87
10:50 ET30051.59
10:53 ET70051.42
10:55 ET102051.51
10:57 ET50051.62
11:02 ET10051.31
11:04 ET30051.56
11:06 ET23351.4
11:08 ET56351.555
11:09 ET20051.69
11:11 ET10051.465
11:15 ET10051.48
11:20 ET10051.57
11:22 ET10051.61
11:24 ET100051.63
11:26 ET40051.79
11:27 ET30052.08
11:29 ET60051.985
11:31 ET70052
11:36 ET10052.125
11:38 ET10052.12
11:40 ET25052.13
11:42 ET348251.975
11:44 ET30052.08
11:45 ET90051.9201
11:47 ET140052.01
11:49 ET40052.015
11:58 ET100051.835
12:00 ET1100351.845
12:02 ET352451.765
12:03 ET104651.735
12:05 ET40051.86
12:07 ET100052.04
12:09 ET50051.945
12:18 ET59151.755
12:20 ET415351.905
12:21 ET232751.9
12:23 ET90052.015
12:25 ET209251.79
12:27 ET600951.86
12:30 ET292252.065
12:36 ET75052.19
12:38 ET28852.3099
12:41 ET50052.22
12:43 ET10052.22
12:50 ET40052.055
12:54 ET12851.92
12:56 ET80052.05
12:57 ET20052.05
12:59 ET20052.23
01:01 ET70052.23
01:06 ET30052.1295
01:08 ET73052.2
01:10 ET20052.03
01:14 ET420852
01:15 ET75952.135
01:17 ET10052.11
01:19 ET10052.28
01:26 ET40052.43
01:33 ET20052.18
01:35 ET60052.13
01:37 ET89952.28
01:42 ET118052.175
01:44 ET190052.0406
01:46 ET2595351.82
01:48 ET250051.62
01:50 ET166251.56
01:53 ET13951.62
01:55 ET30051.57
01:57 ET88051.34
02:00 ET10051.245
02:02 ET10051.215
02:04 ET194851.53
02:11 ET60051.69
02:18 ET10051.7
02:20 ET10051.43
02:22 ET40051.49
02:24 ET220051.49
02:26 ET20051.5
02:27 ET40051.6
02:29 ET161451.51
02:31 ET37551.4
02:38 ET430051.36
02:40 ET55051.41
02:42 ET10051.46
02:49 ET200051.33
02:51 ET150051.1715
02:54 ET40051.04
02:58 ET50050.75
03:03 ET130451.18
03:07 ET234350.752
03:12 ET20050.7
03:16 ET20050.77
03:18 ET10050.71
03:20 ET30050.47
03:23 ET30050.42
03:27 ET135350.33
03:30 ET89850.63
03:38 ET130050.535
03:43 ET258550.73
03:45 ET68750.575
03:48 ET70050.445
03:52 ET121650.64
03:54 ET257650.68
03:56 ET50050.67
03:57 ET257450.66
03:59 ET3066250.64
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPGE
Apogee Therapeutics Inc
3.0B
-22.6x
---
United StatesXENE
Xenon Pharmaceuticals Inc
3.0B
-14.6x
---
United StatesIOVA
Iovance Biotherapeutics Inc
3.0B
-6.2x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesMLTX
MoonLake Immunotherapeutics
3.2B
-56.4x
---
United StatesCLDX
Celldex Therapeutics Inc
2.8B
-15.0x
---
As of 2024-09-17

Company Information

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.

Contact Information

Headquarters
221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
Phone
650-394-5230
Fax
302-655-5049

Executives

Independent Chairman of the Board
Mark Mckenna
Chief Executive Officer, Director
Michael Henderson
Chief Financial Officer
Jane Henderson
Chief Medical Officer
Carl Dambkowski
Independent Director
Lisa Bollinger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.0B
Revenue (TTM)
$0.00
Shares Outstanding
58.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.25
Book Value
$7.86
P/E Ratio
-22.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.